Since 2024: Glaring Reality Keeps AbbVie on Hold
AbbVie’s stock has climbed since 2024, yet a stubborn balance sheet and looming biosimilar erosion create a cautious ...
Which index fund performed best this year? Review top performers, volatility, and potential shifts to inform your next move.
26,831 articlesAbbVie’s stock has climbed since 2024, yet a stubborn balance sheet and looming biosimilar erosion create a cautious ...
Douglas Elliman unveils Elius, a new AI-focused data platform and unit, as part of a sweeping tech overhaul to automa...
JPMorgan’s Jamie Dimon reveals a simple, enduring rule that shaped his ascent from a young Harvard MBA assistant to t...
DraftKings reports a mixed Q1 2026 while signaling growth hinges on prediction markets and regulatory clarity. A path...
SpaceX pursues a bold $1 trillion revenue target by 2031, a goal that has investors and analysts weighing how feasibl...
Analysts point to a stronger data center drive and autos growth as Qualcomm edges toward a new rally. With a $258 tar...
As accel acel 2025 earnings loom, investors seek clarity on revenue, margins, and guidance. This guide breaks down wh...
Broadcom reports a surge in AI semiconductor revenue and points to a path beyond $100 billion in AI-chip sales by 202...
AbbVie blew past first-quarter expectations with a $15.002 billion revenue print and raised full-year guidance, under...
As valuations run high, retirement plans face tighter assumptions. Experts urge conservative return targets and diver...
A fashion brand founder downsizes a high-revenue operation to pursue profitability, exemplifying a growing trend amon...
The T3 Financial Crime Unit, supported by tether, tron labs-backed financial partners, says it has frozen over $450 m...